EA201490627A1 - Соединения для улучшенной вирусной трансдукции - Google Patents

Соединения для улучшенной вирусной трансдукции

Info

Publication number
EA201490627A1
EA201490627A1 EA201490627A EA201490627A EA201490627A1 EA 201490627 A1 EA201490627 A1 EA 201490627A1 EA 201490627 A EA201490627 A EA 201490627A EA 201490627 A EA201490627 A EA 201490627A EA 201490627 A1 EA201490627 A1 EA 201490627A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compounds
viral transduction
compositions
stem cells
Prior art date
Application number
EA201490627A
Other languages
English (en)
Other versions
EA032699B1 (ru
Inventor
Гарретт Коллинс Хеффнер
Абрахам Исаак Бассан
Original Assignee
Блубёрд Био, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47996444&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490627(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Блубёрд Био, Инк. filed Critical Блубёрд Био, Инк.
Publication of EA201490627A1 publication Critical patent/EA201490627A1/ru
Publication of EA032699B1 publication Critical patent/EA032699B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Abstract

В настоящем изобретении предложены способы и композиции для улучшения эффективности трансдукции клеток. В частности, в настоящем изобретении предложены способы и материалы, применимые для безопасного и гарантированного повышения эффективности способов трансдукции клеток, таких как кроветворные стволовые клетки человека (HSC), вирусами и/или вирусными векторами. Композиции и способы применимы при терапевтических показаниях, когда целесообразна генная терапия с использованием кроветворных стволовых клеток.
EA201490627A 2011-09-30 2012-09-28 Способ повышения эффективности трансдукции кроветворных клеток лентивирусом EA032699B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541736P 2011-09-30 2011-09-30
PCT/US2012/057987 WO2013049615A1 (en) 2011-09-30 2012-09-28 Compounds for improved viral transduction

Publications (2)

Publication Number Publication Date
EA201490627A1 true EA201490627A1 (ru) 2014-11-28
EA032699B1 EA032699B1 (ru) 2019-07-31

Family

ID=47996444

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490627A EA032699B1 (ru) 2011-09-30 2012-09-28 Способ повышения эффективности трансдукции кроветворных клеток лентивирусом

Country Status (19)

Country Link
US (4) US9988644B2 (ru)
EP (4) EP2760994B2 (ru)
JP (2) JP6285863B2 (ru)
KR (1) KR102011532B1 (ru)
CN (2) CN103958667A (ru)
AU (1) AU2012315699B2 (ru)
BR (1) BR112014007782B1 (ru)
CA (1) CA2850484C (ru)
CY (1) CY1122654T1 (ru)
DK (2) DK3269802T3 (ru)
EA (1) EA032699B1 (ru)
ES (3) ES2632444T5 (ru)
IL (2) IL231812B (ru)
IN (1) IN2014CN02518A (ru)
MX (2) MX359398B (ru)
PT (2) PT3269802T (ru)
SG (2) SG10201602423TA (ru)
UA (1) UA114796C2 (ru)
WO (1) WO2013049615A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5846915B2 (ja) 2008-11-06 2016-01-20 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 造血幹細胞の生着手順を強化するための材料および方法
MX359398B (es) 2011-09-30 2018-09-27 Bluebird Bio Inc Compuestos para transduccion viral mejorada.
CA2880808C (en) 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
EP3492084B1 (en) 2012-08-01 2021-02-17 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
WO2014026110A2 (en) * 2012-08-10 2014-02-13 Bluebird Bio, Inc. Compounds for improved viral transduction
PT3502240T (pt) 2012-11-27 2021-08-11 Childrens Medical Ct Corp Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal
ES2697573T3 (es) 2013-01-09 2019-01-25 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
SG11201603166UA (en) * 2013-10-24 2016-05-30 Ospedale San Raffaele Srl Method
JP2017511132A (ja) * 2014-03-26 2017-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
BR112016024565A2 (pt) 2014-04-25 2018-01-23 Children's Medical Center Corporation composições e métodos de tratar hemoglobinopatias
ES2835861T3 (es) 2015-05-08 2021-06-23 Childrens Medical Ct Corp Direccionamiento de regiones funcionales del potenciador de BCL11A para la reinducción de hemoglobina fetal
RU2630654C2 (ru) * 2015-07-29 2017-09-11 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов
CN105062979A (zh) * 2015-08-21 2015-11-18 昆明理工大学 一种培养戊型肝炎病毒的方法
MX2018009750A (es) * 2016-02-12 2019-02-07 Bluebird Bio Inc Composiciones potenciadoras de vcn y métodos para su uso.
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
JP2019510503A (ja) * 2016-04-07 2019-04-18 ブルーバード バイオ， インコーポレイテッド キメラ抗原受容体ｔ細胞組成物
IL310250A (en) 2016-05-05 2024-03-01 Liquidia Tech Inc Terfostinil in dry powder form for the treatment of pulmonary hypertension
CA3041514A1 (en) 2016-10-24 2018-05-03 United Therapeutics Corporation Enhancement of msc immunomodulatory properties by treprostinil
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
SG11201908844YA (en) * 2017-03-29 2019-10-30 Bluebird Bio Inc Vectors and compositions for treating hemoglobinopathies
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
CA3075755A1 (en) 2017-09-15 2019-03-21 The Medical College Of Wisconsin, Inc. Kidney-targeted epoxyeicosatrienoic acid (eet) analogs
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
WO2019196816A1 (zh) * 2018-04-13 2019-10-17 诺未科技（北京）有限公司 丁酸钠的用途及含有丁酸钠的培养体系
CN109207427B (zh) * 2018-09-17 2020-12-08 诺未科技（银川）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
KR20210005167A (ko) * 2018-04-27 2021-01-13 더 메디컬 컬리지 오브 위스콘신, 인크. 리소좀 축적병을 완화시키기 위한 렌티벡터-형질도입된 t-rapa 세포의 용도
US20220389448A1 (en) * 2019-06-28 2022-12-08 The Children's Hospital Of Philadelphia Compositions and methods for treating anemia
WO2021076993A1 (en) * 2019-10-16 2021-04-22 Orchard Therapeutics (Europe) Limited Compositions and methods for modifying eukaryotic cells
CN113106098B (zh) * 2021-04-21 2022-04-01 贵州医科大学 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
CN113336833A (zh) * 2021-06-04 2021-09-03 广州伯尼兹生物科技有限公司 一种高效分泌表达猪流行性腹泻病毒s1蛋白的生产方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
WO2024033802A2 (en) 2022-08-11 2024-02-15 Fondazione Telethon Ets Gene therapy
WO2024079644A1 (en) 2022-10-11 2024-04-18 Fondazione Telethon Ets 3d cell culture methods
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568159A (en) 1896-06-26 1896-09-22 Veneering-machine
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
CA2165679A1 (en) 1993-06-21 1995-01-05 Tim M. Townes Anti-sickling hemoglobin
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5869039A (en) 1993-10-15 1999-02-09 Institut National De La Sante Et De La Recherche Medicale X-linked adrenoleukodystrophy gene and corresponding protein
EP0783575B1 (en) 1994-09-19 1999-06-16 Massachusetts Institute Of Technology Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CN1326999C (zh) * 1995-09-29 2007-07-18 印地安纳大学研究及科技有限公司 使用含有病毒和细胞结合区域的分子增强病毒介导的dna转移的方法
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1998000542A2 (en) 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
AU6339399A (en) 1998-10-16 2000-05-08 Novartis Ag Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
AU770867B2 (en) 1999-08-13 2004-03-04 Fumie Sato Prostaglandin derivatives
EP1233986A4 (en) 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
DE60037905T2 (de) 1999-12-17 2009-01-29 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazin-basierte hemmer der glycogen-synthase-kinase 3
DK1132086T3 (da) 2000-01-31 2006-08-28 Pfizer Prod Inc Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
EP1385946B1 (en) 2001-05-01 2009-12-23 National Research Council Of Canada A system for inducible expression in eukaryotic cells
EP1461087A1 (en) 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
EP1468094A4 (en) 2001-12-24 2005-01-26 Es Cell Int Pte Ltd METHOD OF TRANSDUCTING ES CELLS
WO2003065871A2 (en) 2002-02-04 2003-08-14 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE474460T1 (de) 2002-12-13 2010-08-15 Genetix Pharmaceuticals Inc Therapeutische retrovirus-vektoren für gentherapie
AU2004227205B2 (en) 2003-04-08 2010-06-10 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
EP1624899B1 (en) 2003-05-05 2010-11-17 VIRxSYS Corporation INCREASED TRANSDUCTION USING ABC TRANSPORTER SUBSTRATES that are INHIBITORS
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
AU2005299473B2 (en) 2004-10-26 2012-06-28 Allergan, Inc. Therapeutic and delivery methods of prostaglandin EP4 agonists
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
US8076315B2 (en) 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
RU2493252C2 (ru) 2006-03-24 2013-09-20 Чилдрен'З Медикал Сентер Корпорейшн Способ стимулирования экспансии гематопоэтических стволовых клеток
JP5171812B2 (ja) * 2006-04-27 2013-03-27 ユニベルシテ ドゥ モントリオール 移植片対宿主病のリスクの評価および低減
AU2007262382B2 (en) 2006-06-22 2014-05-22 Yeda Research And Development Co. Ltd Catecholamine receptor modulation
JP5426389B2 (ja) 2006-10-20 2014-02-26 チルドレンズ メディカル センター コーポレーション 組織の再生を亢進するための方法
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
ES2703592T3 (es) 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
JP5846915B2 (ja) * 2008-11-06 2016-01-20 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 造血幹細胞の生着手順を強化するための材料および方法
EP2408444A4 (en) 2009-03-19 2012-09-26 Fate Therapeutics Inc COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE
US11459545B2 (en) * 2009-11-15 2022-10-04 Indiana University Research And Technology Corporation Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin E2 receptors
MX359398B (es) * 2011-09-30 2018-09-27 Bluebird Bio Inc Compuestos para transduccion viral mejorada.
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
WO2014026110A2 (en) * 2012-08-10 2014-02-13 Bluebird Bio, Inc. Compounds for improved viral transduction
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
SG11201603166UA (en) * 2013-10-24 2016-05-30 Ospedale San Raffaele Srl Method
CN103937743B (zh) * 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导***获得造血干细胞的方法
WO2016210292A1 (en) * 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
JP2018520688A (ja) * 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
MX2018009750A (es) * 2016-02-12 2019-02-07 Bluebird Bio Inc Composiciones potenciadoras de vcn y métodos para su uso.
WO2017139561A1 (en) * 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
GB201706394D0 (en) * 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques

Also Published As

Publication number Publication date
CN103958667A (zh) 2014-07-30
EP2760994B2 (en) 2021-09-15
MX2018011791A (es) 2021-12-08
SG11201401077PA (en) 2014-04-28
PT3269802T (pt) 2020-01-28
DK3269802T3 (da) 2020-02-03
DK2760994T4 (da) 2021-10-11
US10501759B2 (en) 2019-12-10
PT2760994T (pt) 2017-08-24
JP2014530012A (ja) 2014-11-17
CY1122654T1 (el) 2021-03-12
US10907177B2 (en) 2021-02-02
BR112014007782A2 (pt) 2017-04-11
US11834668B2 (en) 2023-12-05
ES2913633T3 (es) 2022-06-03
AU2012315699B2 (en) 2017-08-17
KR20140069315A (ko) 2014-06-09
MX2014003923A (es) 2014-05-07
IL281045B (en) 2022-02-01
SG10201602423TA (en) 2016-05-30
US9988644B2 (en) 2018-06-05
EP2760994B8 (en) 2017-07-26
CA2850484A1 (en) 2013-04-04
IL231812B (en) 2021-03-25
UA114796C2 (uk) 2017-08-10
NZ623341A (en) 2016-04-29
ES2632444T3 (es) 2017-09-13
EP3269802B1 (en) 2019-10-23
JP6745826B2 (ja) 2020-08-26
ES2769270T3 (es) 2020-06-25
JP2018099124A (ja) 2018-06-28
WO2013049615A1 (en) 2013-04-04
EP3656848A1 (en) 2020-05-27
MX359398B (es) 2018-09-27
DK2760994T3 (en) 2017-08-07
US20180363004A1 (en) 2018-12-20
CA2850484C (en) 2021-01-26
IN2014CN02518A (ru) 2015-07-31
CN108220246A (zh) 2018-06-29
IL281045A (en) 2021-04-29
BR112014007782B1 (pt) 2021-06-01
IL231812A0 (en) 2014-05-28
US20210171980A1 (en) 2021-06-10
EP3656848B1 (en) 2022-03-16
CN108220246B (zh) 2022-07-12
EP2760994A4 (en) 2015-03-11
EA032699B1 (ru) 2019-07-31
EP2760994B1 (en) 2017-05-31
ES2632444T5 (es) 2022-03-02
EP2760994A1 (en) 2014-08-06
US20140234278A1 (en) 2014-08-21
KR102011532B1 (ko) 2019-08-16
EP3269802A1 (en) 2018-01-17
JP6285863B2 (ja) 2018-02-28
AU2012315699A1 (en) 2014-05-22
US20200048657A1 (en) 2020-02-13
EP4095236A1 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
EA201490627A1 (ru) Соединения для улучшенной вирусной трансдукции
WO2014026110A3 (en) Compounds for improved viral transduction
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
MX2013014544A (es) Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia.
EA201890333A1 (ru) Противовирусные соединения
EA202191537A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
EA202193044A2 (ru) Способы лечения таупатии
EA201590868A1 (ru) Противовирусные соединения
EA201590488A1 (ru) Способы модификации клеток-хозяев
MX2014003145A (es) Metodos para el tratamiento de vhc.
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MX2014003889A (es) Compuestos antivirales.
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
GB201020995D0 (en) Biological materials and uses thereof
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
EA201300867A1 (ru) ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
EA201492002A1 (ru) Противовирусные соединения
MX2013008212A (es) Derivados de 7-azaindol.
MX355758B (es) Analogos constreñidos en el anillo como inhibidores de arginasa.
EA201391114A1 (ru) Способы использования alk-ингибиторов
EA201391523A1 (ru) Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток
EA201201177A1 (ru) Димерные ингибиторы iap